WO2000029552A1 - Systeme de couche d'alginate pour la differenciation chondrogene de cellules souches mesenchymateuses de l'homme - Google Patents

Systeme de couche d'alginate pour la differenciation chondrogene de cellules souches mesenchymateuses de l'homme Download PDF

Info

Publication number
WO2000029552A1
WO2000029552A1 PCT/US1999/027129 US9927129W WO0029552A1 WO 2000029552 A1 WO2000029552 A1 WO 2000029552A1 US 9927129 W US9927129 W US 9927129W WO 0029552 A1 WO0029552 A1 WO 0029552A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
mesenchymal stem
alginate
cartilage
cells
Prior art date
Application number
PCT/US1999/027129
Other languages
English (en)
Inventor
Karl Kavalkovich
Raymond Boynton
Mary Murphy
Frank Barry
Original Assignee
Osiris Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics, Inc. filed Critical Osiris Therapeutics, Inc.
Priority to AU16265/00A priority Critical patent/AU1626500A/en
Priority to US09/831,424 priority patent/US6761887B1/en
Publication of WO2000029552A1 publication Critical patent/WO2000029552A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/905—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/56—Fibrin; Thrombin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/80—Hyaluronan

Definitions

  • the present invention relates to the field of methods and compositions for directing human mesenchymal stem cells in vitro and in vivo to differentiate into chondrocytes prior to, or at the time of, or after their implantation into a recipient or host for the therapeutic treatment of articular cartilage defects.
  • MSCs Mesenchymal stem cells
  • the specific differentiation pathway which these cells enter depends upon various influences, such as, mechanical influences and/or endogenous bioactive factors, including growth factors, cytokines, and/or local microenvironmental conditions established by host tissues.
  • a clonal rat fetus calvarial cell line has been shown to differentiate into muscle, fat, cartilage, and bone (Goshima et al., Clin Orthop Rel Res. 269:274-283, 1991). Bone marrow cells form bone and cartilage following their encasement in diffusion chambers and in vivo transplantation (Ashton et al., Clin Orthop Rel Res. 151 :294-307, 1980 (rabbit); Bruder et al, Bone Mineral, 11 :141-151, 1990 (avian)). Cultured chick periosteum cells have been shown to differentiate into cartilage and bone in vitro (Nakahara et al., Exp.
  • Rat bone marrow-derived mesenchymal cells were shown to have the capacity to differentiate into osteoblasts and chondrocytes when implanted in vivo (Dennis et al., Cell Transpl, 1 :2332, 1991; Goshima et al., Clin Orthop Rel Res, 269:274-283, 1991).
  • Pre-molded biodegradable multilayer matrices have been described for repair of articular cartilage, which have been packed into or press-fitted into regularly shaped osteochondral defects (Athanasiou U.S.Pat. No. 5,607,474).
  • Cultured chondrocytes added to a collagen matrix for implantation into an articular cartilage lesion have also been described (Frenkel, SR et al., J Bone Joint Swrg,79-B(5):831 -6 (1997)).
  • Alginate sponges have been used in studies of cartilage repair (see review Messner K. and J. Gilquist, Ada Orthop. Scand 67 (5):523-529 (1996)).
  • Mesenchymal cells from 12 day old mouse limb buds that were phenotypically undifferentiated but committed to differentiate to the chondrocytic lineage in an alginate bead culture system differentiated to cartilage cells and formed a pericellular matrix (Shakibaei, M. and P. De Souza, Cell Biology International, 21(2) 75-86 (1997)).
  • Adult human chondrocytes cultured in alginate beads formed a compartmentalized cartilage matrix (Hauselmann HJ et al., Am. J. Physiol.
  • the construct which supports the differentiation and maturation of human mesenchymal stem cells into chondrocytes.
  • the construct comprises human mesenchymal stem cells in association with a gel and preferably in an alginate suspension.
  • the construct can be utilized for in vivo cartilage regeneration.
  • soluble hyaluronic acid may be added to the construct to support chondrogenesis.
  • composition for regenerating cartilage comprising human mesenchymal stem cells and an alginate gel.
  • the matrix supports the differentiation and maturation of human mesenchymal stem cells into chondrocytes.
  • the construct can be placed in vitro in culture media which will provide conditions favorable for chondrogenic differentiation of the MSCs in the gel.
  • the constructs are cultured in this media and may be modified to determine the effect of specific agents on chondrogenic differentiation and/or the chondrocytic phenotype.
  • the MSCs are added to the gel in vitro under conditions such that the MSCs attach to the gel to form an MSC-gel construct.
  • the construct can then be placed in vivo, i.e. implanted at a target site.
  • the MSCs are not induced to differentiate into chondrocytes prior to implantation.
  • the construct When placed in vivo, the construct will be exposed to naturally occurring chondrogenic inducing factors, found for example in synovial fluid, to stimulate chondrogenic differentiation of the MSCs.
  • the MSCs are added to the alginate solution and the MSC- alginate solution is placed in contact with chondrogenic medium in vitro for a period of time sufficient to direct the MSCs into the chondrogenic lineage.
  • the culture period may be long enough to obtain either mature chondrocytes or may be interrupted at any stage of the chondrogenic differentiation. The entire construct or portions thereof may then be implanted into the defect site.
  • the MSCs are added to the alginate solution and the MSC alginate suspension is spread on a support.
  • the alginate suspension is contacted with a CaCl 2 solution.
  • the alginate polymerizes and forms a gel layer encasing the MSCs.
  • the layer may then be contacted with a chondrogenesis inducing factor.
  • the MSCs can be culture-expanded MSCs, freshly isolated MSCs or unpurified populations of MSCs.
  • the MSCs may further be exposed to at least one chondroinductive agent.
  • Hyaluronic acid may be further added to the above embodiments to support chondrogenesis.
  • the invention also provides a process for producing chondrocytes from mesenchymal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stem cells are associated with the alginate gel and then placed into the implant site.
  • the invention also provides a process for inducing chondrogenesis in mesenchymal stem cells by contacting mesenchymal stem cells with a chondroinductive agent in vitro wherein the stem cells are associated with an alginate gel.
  • the culture period may be long enough to obtain either mature chondrocytes or may be interrupted at any stage of the chondrogenic differentiation.
  • the entire construct or portion of the construct may be delivered to the defect site.
  • the invention further provides a method of repairing or regenerating damaged cartilage, comprising administering to an individual in need thereof a biocompatible construct comprising an alginate gel which supports the differentiation of human mesenchymal stem cells into the chondrogenic lineage.
  • the above methods can also preferably comprise steps where the cells are cultured with the chondroinductive composition and thereafter mixed in alginate gel suspension.
  • the above methods can further comprise steps where the cells are cultured with soluble hyaluronic acid and thereafter are mixed in alginate gel suspension.
  • the MSC-gel layer system may be delivered directly to the implant site without prior induction of differentiation of the MSCs to the chondrogenic lineage.
  • the MSCs are allowed to attach to the gel for a period of up to 24 hours and then implanted without attempting to direct them into the chondrogenic lineage prior to implantation.
  • the MSC-loaded gel is placed into chondrogenic medium in vitro for a finite period to direct the MSCs into the chondrogenic lineage.
  • the culture period may be long enough to obtain mature chondrocytes or may be interrupted at any stage of the chondrogenic differentiation.
  • the entire construct or portions thereof may be delivered to the defect site.
  • Figure 1 illustrates an MSC-alginate-HA suspension layered onto the membrane surface of a transwell insert tissue culture well.
  • Figure 2 illustrates the layer system of MSC-alginate-HA coated transwell in a tissue culture well with complete chondrogenic media and chondrogenesis inducing factor above and incomplete chondrogenic media below the transmembrane layer.
  • Figure 3 shows a cross section view of the alginate-MSC layer after 14 days in culture after histological staining with toluidine-blue, safrinin-O and immunohistochemical staining of collagen Type II tissue.
  • Figure 4. MSCs cultured under chondrogenic conditions in (A) alginate layer and (B) pellets for up to 21 days and then stained for reactivity with a collagen Type Il-specific antibody. (C) Accumulated GAG and rate of biosynthesis measured after 14 days for both alginate and pellet cultures.
  • FIG. 1 Accumulation of GAG and rate of biosynthesis measured as a function of concentration of added HA.
  • the HA concentration ranged from 50 to 1,000 ⁇ g/ml. Measurements were taken after 14 days in culture.
  • Figure 8 Effect of HA on GAG synthesis at varying initial cell densities of MSCs.
  • the present invention provides a composition for the repair of cartilage defects by the rapid regeneration of cartilage tissue.
  • the composition is, for example, inserted or implanted into the defect resulting in articular cartilage regeneration and repair of the defect.
  • the composition comprises an alginate layer in combination with isolated mesenchymal stem cells.
  • the alginate can be combined with the cartilage regenerative cells and optionally other active ingredients by forming a suspension of the MSCs and the alginate where the suspension liquid can have other active ingredients dissolved.
  • Alginate is an unbranched linear polysaccharide consisting of ⁇ -D mannuronic acid and ⁇ - L guluronic acid. It polymerizes and forms a gel in the presence of divalent cations such as Ca " " " .
  • the composition can contain additional components such as chondroinductive factors.
  • the cells and/or the alginate gel can be contacted with a chondroinductive factor.
  • chondroinductive agent or “chondroinductive factor” refers to any natural or synthetic, organic or inorganic chemical or biochemical compound or combination or mixture of compounds, or any mechanical or other physical device, container, influence or force that can be applied to human mesenchymal stem cells which are in a three dimensional format so as to effect their in vitro chondrogenic induction or the production of chondrocytes.
  • the chondroinductive agent is preferably selected, individually or in combination, from the group consisting of (i) a glucocorticoid, such as dexamethasone; and (ii) a member of the transforming growth factor superfamily, such as a bone morphogenic protein (preferably BMP-2 or BMP-4), TGF- ⁇ , inhibin A or chondrogenic stimulating activity factor (CSA).
  • a glucocorticoid such as dexamethasone
  • a member of the transforming growth factor superfamily such as a bone morphogenic protein (preferably BMP-2 or BMP-4), TGF- ⁇ , inhibin A or chondrogenic stimulating activity factor (CSA).
  • the invention also provides a method for treating a cartilage defect in an animal, particularly a mammal, and more particularly a human in need thereof, which comprises administering to the cartilage defect of said animal a cartilage-regenerative amount of the composition of the invention.
  • the cells are contacted with a chondroinductive factor while in the alginate gel layer ex vivo.
  • the method can further comprise administering at least one chondroinductive factor which further induces or accelerates the differentiation of such mesenchymal stem cells into the chondrogenic lineage.
  • the MSCs are first combined with the alginate suspension and polymerized within the gel and are then implanted without induction to chondrogenesis.
  • MSCs are loaded into the alginate and then placed in chondrogenesis- inducing media to induce differentiation prior to delivery to the defect site.
  • This invention has multiple uses and advantages.
  • One such advantage lies in the ability to direct and accelerate MSC differentiation prior to implantation into the host.
  • MSCs which are directed in vitro to become chondrogenic cells will synthesize cartilage matrix at an implant site more rapidly and uniformly than MSCs which must first be recruited into the lineage and then progress through the key differentiation steps.
  • Such an ex vivo treatment also provides for uniform and controlled application of bioactive factors to purified MSCs, leading to uniform lineage commitment and differentiation.
  • Another use of this technique lies in the ability to direct tissue regeneration based on the stage of differentiation of the cells at the time of implantation, which, with respect to cartilage, may control the ultimate tissue type formed.
  • the cells are grown and maintained in a growth or culture medium in which the composition of the invention can undergo in vitro chondrogenesis, particularly in accordance with the methods of the invention, such as serum-free animal cell culture preparation or medium of known composition which will support the viability of human mesenchymal stem cells in vitro.
  • the human mesenchymal stem cells utilized for purposes of the present invention can be derived, for example, from bone marrow. Although these cells are normally present at very low frequencies in bone marrow, a process for isolating, and culture expanding the population of these cells in tissue culture is reported in Caplan et al. U.S. Patent No. 5,486,359.
  • the mesenchymal stem cells are preferably isolated, culture expanded human mesenchymal stem cells in a chemically defined serum- free medium which comprises (1) a chemically defined minimum essential medium (e.g., any of the Eagle's based media, i.e., Dulbecco's Modified Eagle's Medium (DMEM); Iscove's Modified Eagle's Medium, alpha Modified Eagle's Medium, and also McCoy's 5A and BGJb (Fitton-Jackson Modification)); (2) ascorbate or an analog thereof; (3) an iron source; (4) insulin or an insulin-like growth factor; and (5) at least one chondroinductive agent or factor.
  • a chemically defined minimum essential medium e.g., any of the Eagle's based media, i.e., Dulbecco's Modified Eagle's Medium (DMEM); Iscove's Modified Eagle's Medium, alpha Modified Eagle's Medium, and also McCoy's 5A and BG
  • MSCs can be isolated as a non-cultured preparation, such as by density gradient fractionation, from tissue such as bone marrow, blood (including peripheral blood), periosteum and dermis, and other tissues which have mesodermal origins, so as to be substantially free of other types of cells in the marrow.
  • a monoclonal antibody separation is then performed as follows.
  • Dynabeads M-450 (Dynal Inc., Lake Success, NY) are coupled to anti-MSC monoclonal antibodies having ATCC Accession Numbers HB 10743, HB 10744 and HB 10745, by incubating antibody with secondary antibody coated Dynabeads (2.0 g anti-MSC antibody/mg Dynabead; 1 x 10 7 Dynabeads/ml) in PBS for 30 minutes at 4°C.
  • the cells are suspended in a solution of sodium alginate and the suspension is distributed on a semiporous membrane as a layer, the shape and dimensions of which can be easily modified.
  • the alginate mixture is solidified by immersion of the layer and supporting membrane in a pool of calcium chloride.
  • the alginate layer system comprises a component that provides for two separate media-tissue interfaces.
  • This has the advantage of simulating the division of nutritional support seen in vivo between the subchondral vascular supply and the synovial fluid proximal to the articular surface.
  • Nutritional or signalling gradients may be established by manipulating the media formulations in either media compartment. Simple disks of material may be cast and cultured for use as an in vitro testing platform permitting easier sample manipulations and multiple analysis from the same sample. Biochemical, molecular and biomechanical analysis is possible from the same sample.
  • the system is ideally suited for studying the effects of bioactive substances involved in modulating the differentiation of MSCs and represents a format for high throughput screening of substances involved in the turnover of the extracellular matrix molecules in cartilage under normal and osteoarthritic conditions.
  • Construct shape is defined by the dimensions and conformation of the supporting membrane and may be further modified by progressive layering and solidifying of the alginate mixture. Layering in this fashion could also be used to modify cellularity as a function of depth. Thicknesses approaching articular cartilage (0.5-
  • MSCs are culture expanded to appropriate numbers, cast in an alginate layer, sized and shaped to fit an individual's cartilage defect (or larger).
  • the construct is cultured under conditions which are conducive to chondrogenic differentiation.
  • the newly formed chondrocytes express and organize extracellular matrix molecules into a tissue which is comparable to articular cartilage in its responsiveness to physiological and biomechanical stresses.
  • this tissue is surgically implanted or grafted into the site of the defect.
  • EXAMPLE 1 Mesenchymal stem cell were obtained from human bone marrow (Poetic Technologies, Gaithersburg, MD). Following normal expansion culture, 4 x 10 6 hMSCs were spun down and washed with 0.15 M NaCl. The cells were resuspended in 10 ⁇ l sodium alginate (Monsanto, San Diego, CA) (2.4% (v/v) in 0.15 M NaCl, sterilized using a 0.45 ⁇ m filter) and 10 ⁇ l soluble HA (HEALON (Pharmacia, Piscataway, NJ) 2 ⁇ g/ml in sterile MQ H 2 O).
  • transwell membrane 1.0 ⁇ m pore size serves as a support for the layer while the alginate polymerizes and forms a gel when the transwell is immersed in sterile lOOmM CaCl 2 for 10 minutes.
  • Histological staining revealed positive markers of chondrogenesis in >90% of the tissue. Uniform staining by toluidine blue and safranin-O indicated sulfated proteoglycan production. Likewise, evenly distributed immunohistochemical staining of collagen type II indicated a cartilage-like tissue (see Figure 3).
  • TGF- ⁇ 3 stock is made by resuspending lyophilized powder in sterile liquid using siliconized pipet tips and 0.5 ml tubes, l ⁇ g of TGF- ⁇ 3 is resuspended in 50 ⁇ l of 10% ethanol/lOmM HC1, then divided into aliquots and stored at -80° C for up to 2 months.
  • Stocks of AA2P and proline are made by dissolving powder into DMEM and filter-sterilizing. Aliquots of these stocks may be frozen at -20 °C and stored for two weeks.
  • MSCs were isolated from human bone marrow and cultured under chondrogenic conditions in pellet format and in alginate layers. Samples were harvested for immunocytochemical detection of collagen Type II at 7, 14 and 21 days. The cells were seeded on the alginate at a density of 25 x 10 6 cells/ml of alginate gel. Pellets were prepared using 2 x 10 5 cells/pellet. Within the alginate cultures deposition of collagen Type II was evident at day 7 (Fig. 4A) and was distributed uniformly throughout the inter-territorial matrix by day 14. After 21 days, the layer noticeably was thicker with a dense extracellular matrix and the cells were similar morphologically to chondrocytes.
  • the outer periphery of the pellet had cells which were flattened and did not express collagen Type II, an observation that has been made previously.
  • the alginate layer it appeared that all the cells, including those in the superficial zones, were differentiated, showing both chondrocytic morphology and collagen Type II staining.
  • GAG glycosaminoglycans
  • the alginate layer system offers the ideal format for evaluating factors such as cell density because the cultures are prepared as a suspension of cells in liquid alginate.
  • cells were seeded into alginate layers at densities ranging from 1.56 to 50 x 10 6 cells/ml. Each layer was cultured for 14 days under chondrogenic conditions and in the presence of TGF-B3. The rate of
  • Fig. 7 The DNA content was also measured. Some clumping of cells was apparent at all cell densities. At cell seeding densities of less than 6.25x10 6 cells/ml, 35 S-sulfate levels approached background after 14 days in culture (Fig. 7). However, a cell density of 6.25 - 25 x 10 6 cells/ml showed increasing levels of GAG synthesis. At a cell density of 50xl0 6 cells/ml, there was little enhancement in biosynthesis compared to cultures at 25x10 6 cells/ml (Fig. 7).
  • the rate of chondrogenic differentiation is enhanced when MSCs are cultured in alginate layers rather than pellets; (2) the rate of chondrogenesis is enhanced when HA is added at either 100 or 250 ⁇ g/ml to the culture medium; (3) the rate of chondrogenesis is enhanced when cultures in alginate are seeded with cells at a density 25 x 10 6 cells/ml, and reduced at lower densities; (4) the positive effect of added HA is evident at all cell densities up to 50 x 10 6 cells/ml and the magnitude of the effect increases as the cell density decreases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une composition de composants définis chimiquement qui supporte la chondrogénèse in vitro et in vivo de cellules souches mésenchymateuses. L'invention traite également d'un procédé assurant l'induction chondrogènique in vitro et in vivo de ces cellules souches et d'un procédé permettant de former des chondrocytes hymain in vitro et in vivo à partir de ces cellules souches.
PCT/US1999/027129 1998-11-16 1999-11-16 Systeme de couche d'alginate pour la differenciation chondrogene de cellules souches mesenchymateuses de l'homme WO2000029552A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU16265/00A AU1626500A (en) 1998-11-16 1999-11-16 Alginate layer system for chondrogenic differentiation of human mesenchymal stemcells
US09/831,424 US6761887B1 (en) 1998-11-16 1999-11-16 Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10859498P 1998-11-16 1998-11-16
US60/108,594 1998-11-16

Publications (1)

Publication Number Publication Date
WO2000029552A1 true WO2000029552A1 (fr) 2000-05-25

Family

ID=22323057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027129 WO2000029552A1 (fr) 1998-11-16 1999-11-16 Systeme de couche d'alginate pour la differenciation chondrogene de cellules souches mesenchymateuses de l'homme

Country Status (2)

Country Link
AU (1) AU1626500A (fr)
WO (1) WO2000029552A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010348A2 (fr) * 2000-07-29 2002-02-07 Smith & Nephew Plc Implant de tissu
EP1372398A2 (fr) * 2001-02-23 2004-01-02 University of Pittsburgh Preparation rapide de matrices de cellules souches utilisee pour le traitement et la reparation de tissu et d'organe
WO2005023324A1 (fr) * 2003-09-04 2005-03-17 Smith & Nephew Plc Cellules de zones meniscales superficielles utilisees pour reparer un cartilage articulaire
WO2005045008A1 (fr) * 2003-11-07 2005-05-19 Inha University Procede d'induction de chondrogenese sur des cellules souches mesenchymateuses
KR100684932B1 (ko) 2005-04-13 2007-02-20 (주)필미아젠 중간엽 줄기세포와 초음파 자극을 이용하여 연골조직을재생하는 방법
CN100349621C (zh) * 2002-12-18 2007-11-21 上海第二医科大学附属第九人民医院 骨髓基质干细胞诱导成软骨的方法
WO2008004260A3 (fr) * 2006-05-31 2008-07-10 Biorigen S R L Biomembrane destinée à la régénération tissulaire
WO2009017267A1 (fr) * 2007-08-01 2009-02-05 Regenprime Co., Ltd. Procédé de différenciation de cellules souches mésenchymes et de culture de chondrocytes par le biais de composite fibrine/ha revêtu d'alginate
US7887792B2 (en) 1998-05-01 2011-02-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
US8105834B2 (en) 2007-01-11 2012-01-31 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same
CN102409024A (zh) * 2010-09-25 2012-04-11 上海市计划生育科学研究所 构建前列腺癌细胞体外浸润模型
US8211423B2 (en) 2006-11-28 2012-07-03 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US8580561B2 (en) 1998-05-01 2013-11-12 University of Pittsburgh—of the Commonwealth System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
CN104857564A (zh) * 2015-04-27 2015-08-26 中国科学院遗传与发育生物学研究所 一种引导尿道再生的功能性生物支架材料及其制备方法
US9121009B2 (en) 2006-12-18 2015-09-01 University of Pittsburgh—Of the Commonweath System of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US9199003B2 (en) 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
WO2016077118A1 (fr) * 2014-11-10 2016-05-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Technologies à base de cellules souches pour l'ingénierie et la régénération de tissu squelettique aviaire
US9499791B2 (en) 1998-05-01 2016-11-22 University of Pittsburgh—of the Commonwealth System of Higher Education Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
US9617516B2 (en) 2003-04-25 2017-04-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration
US11291690B2 (en) 2006-12-18 2022-04-05 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
CN115135318A (zh) * 2019-12-20 2022-09-30 Trb化药国际股份有限公司 “透明质酸衍生物在骨和软骨组织的再生中的用途”

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028539A1 (fr) * 1995-03-14 1996-09-19 Morphogen Pharmaceuticals, Inc. Cellules souches mesenchymateuses pour la reparation de cartilages
WO1998025653A2 (fr) * 1996-12-10 1998-06-18 Reprogenesis, Inc. Hydrogel ameliore pour la creation de tissu
WO1998032333A1 (fr) * 1996-12-06 1998-07-30 Osiris Therapeutics, Inc. Perfectionnement concernant la differentiation chondrogene de cellules souches du mesenchyme humain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028539A1 (fr) * 1995-03-14 1996-09-19 Morphogen Pharmaceuticals, Inc. Cellules souches mesenchymateuses pour la reparation de cartilages
WO1998032333A1 (fr) * 1996-12-06 1998-07-30 Osiris Therapeutics, Inc. Perfectionnement concernant la differentiation chondrogene de cellules souches du mesenchyme humain
WO1998025653A2 (fr) * 1996-12-10 1998-06-18 Reprogenesis, Inc. Hydrogel ameliore pour la creation de tissu

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORLAND , K. ET AL.: "Injectable Hydrogels Containing Autologous Chondrocytes as Engineered Tissue Bulking Agents", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 34, March 1998 (1998-03-01), pages 28A, XP000881997 *
HÄUSELMANN, H.J. ET AL.: "Adult human chondrocytes cultured in alginate form a matrix similar to native human articular cartilage", AMERICAN JOURNAL OF PHYSIOLOGY: CELL PHYSIOLOGY, vol. 271, no. 3, September 1996 (1996-09-01), pages C742 - C752, XP000882049 *
JOHNSTONE, B. ET AL.,: "In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells", EXPERIMENTAL CELL RESEARCH, vol. 238, no. 1, 10 January 1998 (1998-01-10), pages 265 - 272, XP000882426 *
KUJAWA M J ET AL: "SUBSTRATE-BONDED HYALURONIC-ACID EXHIBITS A SIZE-DEPENDENT STIMULATION OF CHONDROGENIC DIFFERENTIATION OF STAGE 24 LIMB MESENCHYMAL CELLS IN CULTURE", DEVELOPMENTAL BIOLOGY 1986, vol. 114, no. 2, 1986, pages 519 - 528, XP000882647, ISSN: 0012-1606 *
SHAKIBAEI, M. AND P. DE SOUZA: "Differentiation of mesenchymal limb bud cells to chondrocytes in alginate beads", CELL BIOLOGY INTERNATIONAL, vol. 21, no. 2, 1997, pages 75 - 86, XP000881943 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887792B2 (en) 1998-05-01 2011-02-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
US8741277B2 (en) 1998-05-01 2014-06-03 University of Pittsburgh—of the Commonwealth System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US8580561B2 (en) 1998-05-01 2013-11-12 University of Pittsburgh—of the Commonwealth System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US9352004B2 (en) 1998-05-01 2016-05-31 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
US8765120B2 (en) 1998-05-01 2014-07-01 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle-derived cells (MDCS) for augmenting or bulking urethral sphincter-muscle tissue
US9410124B2 (en) 1998-05-01 2016-08-09 University of Pittsburgh—of the Commonwealth System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US8685385B2 (en) 1998-05-01 2014-04-01 Univeristy of Pittsburgh—of the Commonwelath System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
US9499791B2 (en) 1998-05-01 2016-11-22 University of Pittsburgh—of the Commonwealth System of Higher Education Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
US8986671B2 (en) 1998-05-01 2015-03-24 University of Pittsburgh—of the Commonwealth System of Higher Education Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
WO2002010348A2 (fr) * 2000-07-29 2002-02-07 Smith & Nephew Plc Implant de tissu
WO2002010348A3 (fr) * 2000-07-29 2002-09-06 Smith & Nephew Implant de tissu
US9452238B2 (en) 2000-07-29 2016-09-27 Smith & Nephew LLP Tissue implant
US8790680B2 (en) 2001-02-23 2014-07-29 University of Pittsburg—Of the Commonwealth System of Higher Education Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
US7906110B2 (en) 2001-02-23 2011-03-15 University of Pittsburgh—of the Commonwealth System of Higher Education Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
EP1372398A4 (fr) * 2001-02-23 2009-06-24 Univ Pittsburgh Preparation rapide de matrices de cellules souches utilisee pour le traitement et la reparation de tissu et d'organe
EP1372398A2 (fr) * 2001-02-23 2004-01-02 University of Pittsburgh Preparation rapide de matrices de cellules souches utilisee pour le traitement et la reparation de tissu et d'organe
JP2007275613A (ja) * 2001-02-23 2007-10-25 Univ Of Pittsburgh 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
JP2004524029A (ja) * 2001-02-23 2004-08-12 ザ ユニバーシティ オブ ピッツバーグ 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
CN100349621C (zh) * 2002-12-18 2007-11-21 上海第二医科大学附属第九人民医院 骨髓基质干细胞诱导成软骨的方法
US9617516B2 (en) 2003-04-25 2017-04-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration
WO2005023324A1 (fr) * 2003-09-04 2005-03-17 Smith & Nephew Plc Cellules de zones meniscales superficielles utilisees pour reparer un cartilage articulaire
WO2005045008A1 (fr) * 2003-11-07 2005-05-19 Inha University Procede d'induction de chondrogenese sur des cellules souches mesenchymateuses
KR100684932B1 (ko) 2005-04-13 2007-02-20 (주)필미아젠 중간엽 줄기세포와 초음파 자극을 이용하여 연골조직을재생하는 방법
WO2008004260A3 (fr) * 2006-05-31 2008-07-10 Biorigen S R L Biomembrane destinée à la régénération tissulaire
US8211423B2 (en) 2006-11-28 2012-07-03 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US9121009B2 (en) 2006-12-18 2015-09-01 University of Pittsburgh—Of the Commonweath System of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US11291690B2 (en) 2006-12-18 2022-04-05 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US8961954B2 (en) 2007-01-11 2015-02-24 Michael B. Chancellor Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
US8105834B2 (en) 2007-01-11 2012-01-31 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same
WO2009017267A1 (fr) * 2007-08-01 2009-02-05 Regenprime Co., Ltd. Procédé de différenciation de cellules souches mésenchymes et de culture de chondrocytes par le biais de composite fibrine/ha revêtu d'alginate
US9199003B2 (en) 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
CN102409024A (zh) * 2010-09-25 2012-04-11 上海市计划生育科学研究所 构建前列腺癌细胞体外浸润模型
WO2016077118A1 (fr) * 2014-11-10 2016-05-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Technologies à base de cellules souches pour l'ingénierie et la régénération de tissu squelettique aviaire
US10864234B2 (en) 2014-11-10 2020-12-15 University of Pittsburgh—of the Commonwealth System of Higher Education Stem cell-based technologies for avian skeletal tissue engineering and regeneration
CN104857564A (zh) * 2015-04-27 2015-08-26 中国科学院遗传与发育生物学研究所 一种引导尿道再生的功能性生物支架材料及其制备方法
CN115135318A (zh) * 2019-12-20 2022-09-30 Trb化药国际股份有限公司 “透明质酸衍生物在骨和软骨组织的再生中的用途”

Also Published As

Publication number Publication date
AU1626500A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
US6761887B1 (en) Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
US6482231B1 (en) Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
WO2000029552A1 (fr) Systeme de couche d'alginate pour la differenciation chondrogene de cellules souches mesenchymateuses de l'homme
TWI283707B (en) Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
US6489165B2 (en) Chondrocyte-like cells useful for tissue engineering and methods
US5226914A (en) Method for treating connective tissue disorders
US5197985A (en) Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
CA2251983C (fr) Regeneration et croissance osseuse obtenues a l'aide de cellules souches du mesenchyme
US7863045B2 (en) Isolation of skeletal precursor cells
Hannouche et al. Engineering of implantable cartilaginous structures from bone marrow–derived mesenchymal stem cells
JP2003510108A (ja) 生物学的関節構造体
JP2019088302A (ja) 単離された椎間板細胞、その使用方法、および哺乳動物組織からそれを調製する方法
AU2004261899A1 (en) Scaffold-free self-organized 3D synthetic tissue
KR102479530B1 (ko) 인간 유도 만능 줄기세포로부터 연골세포의 펠렛을 제조하는 방법 및 이의 용도
EP3025735B1 (fr) Procédés de génie tissulaire complexes
US20030215426A1 (en) Redifferentiated cells for repairing cartilage defects
JP4763960B2 (ja) ヒト軟骨細胞培養方法
MXPA97005612A (en) Induction directed by lineage of the differentiation of human mesenquimatosas cells of ori

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16265

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09831424

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase